(Q53177911)

12 May 2018

title

The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. (English)

1 reference

12 May 2018

0 references

Joseph Jackson

1

1 reference

12 May 2018

J Jaime Caro

2

1 reference

12 May 2018

Graciela Caro

3

1 reference

12 May 2018

Frances Garfield

4

1 reference

12 May 2018

Ferdinand Huber

5

1 reference

12 May 2018

Wenjiong Zhou

6

1 reference

12 May 2018

Chen-Sheng Lin

7

1 reference

12 May 2018

Douglas Shander

8

1 reference

12 May 2018

Kathy Schrode

9

1 reference

12 May 2018

Eflornithine HCl Study Group

10

1 reference

12 May 2018

publication date

1 September 2007

1 reference

12 May 2018

International Journal of Dermatology

published in

1 reference

12 May 2018

volume

46

1 reference

12 May 2018

issue

9

1 reference

12 May 2018

page(s)

976-981

1 reference

12 May 2018

Psychological morbidity in women referred for treatment of hirsutism

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Microsurgical ablative procedures in the peripheral nerves and dorsal root entry zone for relief of focal spasticity in the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

21 January 2018

Anxiety and hirsutism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Rehabilitation care and outcomes from the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Patient-centered outcomes in surgical and orthodontic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Evaluating quality-of-life and health status instruments: development of scientific review criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Interpretation of quality of life changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Measurement of health status. Ascertaining the minimal clinically important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

Interpreting treatment effects in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2007.03270.X

10.1111/J.1365-4632.2007.03270.X

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018